AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-22. (canceled)

23. (currently amended) A method for the enhancement of enhancing cognitive function and alleviation of alleviating mental fatigue, said method comprising[[:]] administering, to a subject in need thereof, an effective amount of a Ginkgo-phospholipid complex, said complex comprising Ginkgo complexed with a phospholipid containing 10 to 50% of 20% phosphatidylserine.

24-25. (canceled)

- 26. (previously presented) The method according to claim 23, wherein the Ginkgo is derived from the plant *Ginkgo biloba*, extracts thereof and/or one or more principal active substances thereof.
- 27. (previously presented) The method according to claim 26, wherein one of the principal active substances is bilobalide.

Docket No. 2503-1225 Appln. No. 10/587,468

- 28. (currently amended) The method according to claim 26, wherein the Ginkgo extract contains at least about 20% Ginkgo flavone glycosides and about $\frac{2}{2}$ to about $\frac{2}{2}$ -10% terpene lactones.
- 29. (currently amended) The method according to claim 23, wherein the ratio between Ginkgo and the phosphatidylserine in the complex is about 1:3.
- 30. (currently amended) The method according to claim 23, wherein the Ginkgo-phospholipid complex is in a medicament or a dietary supplement that is administered in the form of tablets, granules, powders, capsules, syrups, solutions, suspensions, dragees, gels, injections or drops.
- 31. (currently amended) The method according to claim 23, wherein the Ginkgo-phospholipid complex is in a medicament or a dietary supplement and is formulated for oral administration.
- 32. (currently amended) The method according to claim 23, wherein the Ginkgo-phospholipid phosphatidylserine complex is in a medicament or a dietary supplement that is administered in an amount of about 20 to about 20-240 mg per day, or in an amount of about 60-120 mg per day.

- 33. (currently amended) The method according to claim 23, wherein the Ginkgo_phospholipid complex is in a medicament or a dietary supplement, and further contains a pharmaceutically acceptable amount of at least one additive selected from the group consisting of minerals, vitamins, sweeteners, flavors, pharmaceutically acceptable carriers, auxiliary and binder agents, excipients and mixtures thereof.
- 34. (currently amended) The method according to claim 33, wherein the additive is selected from the group consisting of vitamins, minerals and mixtures thereof, and/or is selected from calcium, fluorine, phosphorus, copper, potassium, manganese, magnesium selenium, zinc and iron, Vitamin A, Vitamins B1, B2 and B12, Vitamin C, Vitamin D2, nicotinamide, calcium pantotenate, rutoside and Vitamin E.
- 35. (currently amended) A method for the enhancement of cognitive function and alleviation of mental fatigue by improving the speed of memory speed and memory quality, by counteracting cognitive fatigue in a normal, healthy human, persons or by preventing reducing deterioration of the speed of memory speed and memory quality in people a human with decreased cognitive functions, said method comprising administering, to a subject in need thereof, an effective amount of [[a]] Ginkgo complexed with phosphatidylserine.

Docket No. 2503-1225 Appln. No. 10/587,468

- 36. (currently amended) A method for the treatment and prevention of treating a disease related with the reduction of to reduced cognitive function and increased mental fatigue, said method comprising administering, to a subject in need thereof, an effective amount of [[a]] Ginkgo complexed with phosphatidylserine.
- 37. (previously presented) The method according to claim 36, wherein the disease is Dementia.
- 38. (previously presented) The method according to claim 37, wherein the disease is Alzheimer's Disease.
- 39. (currently amended) The method according to claim 36, wherein the Ginkgo-phosphatidylserine complex is in a medicament or a dietary supplement, and further contains a pharmaceutically acceptable amount of at least one additive selected from the group consisting of vitamins, minerals, sweeteners, flavors, pharmaceutically acceptable carriers, auxiliary and binder agents, excipients and mixtures thereof.
- 40. (currently amended) The method according to claim 36, further comprising administering [[a]] an additional pharmaceutical compound used for the treatment and prevention of

treating the disease to be treated related with the reduction of to reduced cognitive function and increased mental fatigue.

- 41. (currently amended) The method according to claim 40, wherein the <u>additional</u> pharmaceutical compound is an acetylcholinesterase inhibitor.
- **42.** (currently amended) The method according to claim 40, further comprising administering complexed grape seed extract, as an additionally active compound, to the subject.
- 43. (withdrawn) A pharmaceutical or dietary composition comprising *Ginkgo* complex and at least one vitamin and a pharmaceutically or dietarily acceptable carrier.
- 44. (withdrawn) A complex of an extract of *Ginkgo* with a phosphatidylserine of formula

wherein R and R^1 each independently represent an acyl moiety selected from the fatty acids consisting of palmitic acid, oleic acid, linoleic acid, stearic acid.

Docket No. 2503-1225 Appln. No. 10/587,468

- 45. (withdrawn) A complex according to claim 44, which comprises from 15 to 25% of saturated fatty acids, from 5 to 15% of mono-unsaturated fatty acids and from 60 to 80% of polyunsaturated fatty acids, based on the total acids.
- **46.** (currently amended) The method of claim 23, wherein the ratio between Ginkgo and the phosphatidylserine is 0.5-1: 2-5.